Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › PHIO

Phio Pharmaceuticals

PHIO Lead: Phase 1 ★ Read the deep dive → 4 Biotech Distilled articles ↓ 32 filings & releases ↓ Cash $10.6M (Sep 30, 2026) ↓ 4 verdicts ↓ 1 timing quote ↓
Oncology Nucleic Acid

Market cap $9.6M 12.0M shares (10-Q, Nov 3, 2026) × $0.801 close Nov 6, 2026

Most recent annual filing: 2026-03-15

Catalyst timeline

2 trackedQuarter catalyst calendar →
  1. PH-762 corporate update2026PH-762 corporate update, 2026, routine
  2. PH-762 manufacturing update2H 2026PH-762 manufacturing update, 2H 2026, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (4 active programs)

Technology platforms

INTASYL

Proprietary self-delivering small interfering RNA (siRNA) gene silencing platform. Chemically modified siRNAs with spontaneous cellular uptake — no formulations, nanoparticles, or electroporation required. Targets a broad range of cell types and tissues; designed for immuno-oncology applications including direct-to-tumor injection and adoptive cell therapy (ACT). Demonstrated preclinical activity against PD-1, BRD4, CTLA-4, TIGIT, and CTGF.

Targets: PD-1, BRD4, CTLA-4, TIGIT, CTGF

Capital (as filed)

Cash
$10.6M cash and cash equivalents · Sep 30, 2026 (10-Q)
Operating cash flow
−$2.3M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$10.6M cash per the update of Nov 5, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (4)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (4 calls)

Every verdict Biotech Distilled has published on Phio Pharmaceuticals, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-04-15 Avoid Phio Pharmaceuticals (PHIO) - Scientific Deep Dive for PH-762 and Pipeline Products The science is legitimate but the equity is uninvestable for fundamentals-driven investors due to relentless dilution and warrant overhang; only a watch/pass for binary-event traders.
  2. 2026-05-08 Avoid UPDATE: Phio Pharmaceuticals (PHIO) - The ORR Keeps Shrinking The cSCC complete response rate has been walked down to 45% (9/20), burn tripled YoY against a flat cash balance, and the ATM dilution machine is loaded; the equity is now explicitly uninvestable.
  3. 2026-08-07 Avoid UPDATE: Phio Pharmaceuticals (PHIO) - The FDA Meeting That Keeps Moving The FDA meeting slipped a quarter, burn tripled YoY into a shrinking $13M cash balance, and the 45% CR efficacy anchor is unchanged; genuine tox/cGMP progress does not offset the cap structure risk.
  4. 2026-09-15 Avoid UPDATE: Phio Pharmaceuticals (PHIO) - The Package Finally Ships FDA briefing package submitted and tox dosing complete are real progress, but the efficacy anchor remains 45% CR in a single-arm n=20 study and the Phase 2b is unfunded from a $13M base.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (1 quote from 1 filing)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (32)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Jun 18, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

2 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)